Gentian’s CSO Aleksandra Havelka will present the poster “Health economic impact of use of calprotectin immunoassay for early detection of infection intensive care patients”* at the 42nd ISICEM - International Symposium on Intensive Care & Emergency Medicine in Brussels March 21-24th.
The full poster, with more detailed results, will be presented at the poster session March 21st 18:00-19:30. We look forward to see you there!
*Authors:
A. Havelka - Gentian Diagnostics, Stockholm, Sweden; M. Lipcsey and M. Hultström - Uppsala University, Department of Surgical Sciences, Anaesthesiology, Uppsala, Sweden and A. Larsson- Akademiska University Hospital, Department of Medical Sciences, Clinical Chemistry, Uppsala, Sweden.
The challenge with early diagnosis of bacterial infections in critically ill patients
Early diagnosis of bacterial infections in critically ill patients is challenging, as the clinical manifestation is nonspecific. Earlier studies have shown the ability of calprotectin to predict bacterial infections before onset of clinical symptoms. With early diagnosis of bacterial infections delayed treatment will be avoided as well as clinical deterioration due to severe infections/sepsis.
Estimation of the cost-effectiveness of calprotectin
The analysis is based on patients admitted to an Intensive Care Unit (ICU) in a Swedish hospital through a decision tree model. The model is employed to estimate the cost-effectiveness of calprotectin analysis for early detection of bacterial infection and thus, the earlier start of antibiotic treatment compared to other diagnostic biomarkers.
Comparison with conventional biomarkers
The comparators included in the analysis are white blood cell count (WBC), procalcitonin (PCT), C-reactive protein (CRP), and no testing.
Use of calprotectin in the ICU saves total costs, reduces mean duration of in-patient care and mortality
The base-case results show that predictively measuring of calprotectin in an ICU saves total costs, reduces mean duration of in-patient care and mortality, compared with the comparators. The base-case scenario identified calprotectin, measured with Gentian’s GCAL® Calprotectin Immunoassay as cost effective biomarker for a patient cohort presented in a Swedish ICU. In the sensitivity analysis, when key model inputs are varied, calprotectin remains the dominant option.
The full poster, with more detailed results, will be presented at the poster session March 21st 18:00-19:30. We look forward to see you there!
GCAL® - Calprotectin assay for plasma and serum
GCAL®, Gentian's plasma and serum calprotectin assay is applied to turbidimetry-based clinical chemistry platforms. It is an open channel assay, meaning it can be added to most clinical chemistry analysers.
- CE-marked since 2017
- IVDR certified
- Developed and manufactured by Gentian
- Manufactured according to ISO 13485:2016
Contact us for further information
Explore GCAL® in your laboratory - fill out the form or send an email to marketing@gentian.com for more information about the product and prices.
